Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
Overview[ - collapse ][ - ]
Purpose | The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis. |
---|---|
Condition | Deep-Vein Thrombosis |
Intervention | Drug: Apixaban |
Phase | Phase 2 |
Sponsor | Bristol-Myers Squibb |
Responsible Party | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier | NCT00252005 |
First Received | November 9, 2005 |
Last Updated | February 27, 2010 |
Last verified | August 2008 |
Tracking Information[ + expand ][ + ]
First Received Date | November 9, 2005 |
---|---|
Last Updated Date | February 27, 2010 |
Start Date | November 2005 |
Estimated Primary Completion Date | February 2007 |
Current Primary Outcome Measures |
|
Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
Brief Title | Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study |
---|---|
Official Title | Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis |
Brief Summary | The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis. |
Detailed Description | Not Provided |
Study Type | Interventional |
Study Phase | Phase 2 |
Study Design | Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment |
Condition | Deep-Vein Thrombosis |
Intervention | Drug: Apixaban |
Study Arm (s) | Not Provided |
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 520 |
Estimated Completion Date | February 2007 |
Estimated Primary Completion Date | February 2007 |
Eligibility Criteria | Inclusion Criteria: 1. Subjects must be willing and able to give written informed consent. 2. Confirmed acute symptomatic DVT, i.e., proximal vein or extensive calf-vein thrombosis, involving at least the upper third part of the deep calf veins (trifurcation area) without concomitant symptomatic PE. 3. Women and men, ages 18 (or legal age of consent) to 90. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 1 week after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea for 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35mIU/mL]. Even women who are using oral, implanted or, injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 24 hours prior to the start of study medication. Exclusion Criteria: 1. Women who are pregnant or breastfeeding. 2. Women with a positive pregnancy test on enrollment or prior to study drug administration. 3. More than 24 hours pre-randomization treatment with therapeutic dosages of unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or more than a single starting dose of vitamin K antagonist (VKA) prior to randomization. 4. Uncontrolled hypertension: systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg. 5. Creatinine clearance < 30 mL/min 6. Impaired liver function (ALT > 3 x ULN) 7. Use of ASA > 165 mg/day 8. WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 1 week after the study. 9. Azole antifungals (e.g., ketoconazole), HIV protease inhibitors (e.g., ritonavir) and macrolide antibiotics (e.g., erythromycin). NOTE: topical azole antifungal agents are permitted. |
Gender | Both |
Ages | 18 Years |
Accepts Healthy Volunteers | No |
Contacts | Not Provided |
Location Countries | United States, Australia, Austria, Czech Republic, France, Israel, Italy, Netherlands, Poland, South Africa, Sweden |
Administrative Information[ + expand ][ + ]
NCT Number | NCT00252005 |
---|---|
Other Study ID Numbers | CV185-017 |
Has Data Monitoring Committee | Not Provided |
Information Provided By | Bristol-Myers Squibb |
Study Sponsor | Bristol-Myers Squibb |
Collaborators | Not Provided |
Investigators | Not Provided |
Verification Date | August 2008 |
Locations[ + expand ][ + ]
Local Institution | Albuquerque, New Mexico, United States |
---|---|
Local Institution | Chapel Hill, North Carolina, United States |
Local Institution | San Antonio, Texas, United States |
Local Institution | Fredericksburg, Virginia, United States |
Local Institution | Seattle, Washington, United States |
Local Institution | Garran, Australian Capital Territory, Australia |
Local Institution | Caringbah, New South Wales, Australia |
Local Institution | Kogarah, New South Wales, Australia |
Local Institution | Randwick, New South Wales, Australia |
Local Institution | Bedford Park, South Australia, Australia |
Local Institution | Box Hill, Victoria, Australia |
Local Institution | Clayton, Victoria, Australia |
Local Institution | Melbourne, Victoria, Australia |
Local Institution | Perth, Western Australia, Australia |
Local Institution | Graz, Austria |
Local Institution | Wien, Austria |
Local Institution | Hradec Kralove, Czech Republic |
Local Institution | Karlovy Vary, Czech Republic |
Local Institution | Ostrava 1, Czech Republic |
Local Institution | Ostrava Poruba, Czech Republic |
Local Institution | Plzen, Czech Republic |
Local Institution | Praha 1, Czech Republic |
Local Institution | Praha 2, Czech Republic |
Local Institution | Usti Nad Labem, Czech Republic |
Local Institution | Angers, France |
Local Institution | Brest Cedex, France |
Local Institution | Clermont-Ferrand Cedex 01, France |
Local Institution | Creteil, France |
Local Institution | Limoges, France |
Local Institution | Montpellier, France |
Local Institution | Paris, France |
Local Institution | Saint Etienne, France |
Local Institution | Afula, Israel |
Local Institution | Ashkelon, Israel |
Local Institution | Haifa, Israel |
Local Institution | Holon, Israel |
Local Institution | Jerusalem, Israel |
Local Institution | Kfar-Saba, Israel |
Local Institution | Petach Tikva, Israel |
Local Institution | Safed, Israel |
Local Institution | Tel Aviv, Israel |
Local Institution | Chieti, Italy |
Local Institution | Milano, Italy |
Local Institution | Padova, Italy |
Local Institution | Pavia, Italy |
Local Institution | Piacenza, Italy |
Local Institution | Reggio Emilia, Italy |
Local Institution | Treviso, Italy |
Local Institution | Venezia, Italy |
Local Institution | Amsterdam, Netherlands |
Local Institution | Arnhem, Netherlands |
Local Institution | Groningen, Netherlands |
Local Institution | Hoofddorp, Netherlands |
Local Institution | Maastricht, Netherlands |
Local Institution | Zwolle, Netherlands |
Local Institution | Bydgoszcz, Poland |
Local Institution | Katowice, Poland |
Local Institution | Krakow, Poland |
Local Institution | Lublin, Poland |
Local Institution | Poznan, Poland |
Local Institution | Warszawa, Poland |
Local Institution | Wroclaw, Poland |
Local Institution | Bloemfontein, Free State, South Africa |
Local Institution | Centurion, Gauteng, South Africa |
Local Institution | Johannesburg, Gauteng, South Africa |
Local Institution | Sunninghill, Gauteng, South Africa |
Local Institution | Somerset West, Western Cape, South Africa |
Local Institution | Boras, Sweden |
Local Institution | Goteborg, Sweden |
Local Institution | Halmstad, Sweden |
Local Institution | Jonkoping, Sweden |
Local Institution | Stockholm, Sweden |
Local Institution | Vastervik, Sweden |